Bottom line
MEDX vs PRHSX: the short answer
MEDX (Horizon Kinetics Medical ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both etfs.
But PRHSX is far broader, holding 279 positions to 33 for MEDX, so beyond the top names it adds exposure MEDX doesn't have.
PRHSX is cheaper at 0.83% vs 0.85% — a difference of $2.00 a year per $10,000 invested.
Over five years, MEDX returned +5.8% a year vs +4.2% for PRHSX.
Updated Nov 19, 2026
MEDX vs PRHSX side by side
| MEDX | PRHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Roundhill | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.85% | 0.83% |
| Annual cost per $10k | $85 | $83 |
| 10-yr cost on $10k (prospectus) | $1,049 | $1,025 |
| Max front load | None | — |
| 12b-1 fee | 0% | — |
| 1-yr return | +28.4% | +17.7% |
| 5-yr return (annualized) | +5.8% | +4.2% |
| 10-yr return (annualized) | +5.7% | +9.1% |
| Best quarter | +15.0% | +23.5% |
| Worst quarter | −12.9% | −15.8% |
| Net assets (fund) | $19.1M | $11.9B |
| Number of holdings | 33 | 279 |
| Portfolio turnover | % | 62% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | MEDX | PRHSX | Difference |
|---|---|---|---|
| 2025 | +28.4% | +17.7% | +10.7% |
| 2024 | −4.7% | +1.8% | −6.5% |
| 2023 | −6.0% | +3.1% | −9.1% |
| 2022 | +4.2% | −12.2% | +16.4% |
| 2021 | +10.6% | +13.3% | −2.7% |
| 2020 | +9.0% | +30.1% | −21.1% |
| 2019 | +16.0% | +29.1% | −13.1% |
| 2018 | +1.7% | +1.2% | +0.4% |
| 2017 | +10.7% | +28.0% | −17.2% |
| 2016 | −8.0% | −10.4% | +2.3% |
Source: Fund prospectus bar charts
Holdings overlap
6 of MEDX's top 25 holdings also appear in PRHSX's top 25.
| Holding | MEDX | PRHSX |
|---|---|---|
| Eli Lilly & Co | 18.46% | 14.28% |
| AbbVie Inc | 8.85% | 5.10% |
| Johnson & Johnson | 5.59% | 6.63% |
| Bristol-Myers Squibb Co | 4.42% | 2.11% |
| Merck & Co Inc | 3.96% | 4.01% |
| Amgen Inc | 3.91% | 1.82% |
Source: SEC Form N-PORT
MEDX top 10
- Eli Lilly & Co — 18.46%
- US Bank Mmda - Usbgfs 7 — 9.19%
- AbbVie Inc — 8.85%
- Novartis AG — 6.89%
- Johnson & Johnson — 5.59%
- Alkermes PLC — 5.53%
- AstraZeneca PLC — 4.98%
- Ionis Pharmaceuticals Inc — 4.53%
- Bristol-Myers Squibb Co — 4.42%
- Merck & Co Inc — 3.96%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between MEDX and PRHSX?
Which is cheaper, MEDX or PRHSX?
Should I own both MEDX and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.